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Abstract
Background: Williams-Beuren Syndrome (WBS) is a neurodevelopmental disorder caused by a hemizygous deletion of a
1.5 Mb region on chromosome 7q11.23 encompassing 26 genes. One of these genes, GTF2IRD1, codes for a putative
transcription factor that is expressed throughout the brain during development. Genotype-phenotype studies in patients
with atypical deletions of 7q11.23 implicate this gene in the neurological features of WBS, and Gtf2ird1 knockout mice show
reduced innate fear and increased sociability, consistent with features of WBS. Multiple studies have identified in vitro target
genes of GTF2IRD1, but we sought to identify in vivo targets in the mouse brain.
Methodology/Principal Findings: We performed the first in vivo microarray screen for transcriptional targets of Gtf2ird1 in
brain tissue from Gtf2ird1 knockout and wildtype mice at embryonic day 15.5 and at birth. Changes in gene expression in
the mutant mice were moderate (0.5 to 2.5 fold) and of candidate genes with altered expression verified using real-time
PCR, most were located on chromosome 5, within 10 Mb of Gtf2ird1. siRNA knock-down of Gtf2ird1 in two mouse neuronal
cell lines failed to identify changes in expression of any of the genes identified from the microarray and subsequent analysis
showed that differences in expression of genes on chromosome 5 were the result of retention of that chromosome region
from the targeted embryonic stem cell line, and so were dependent upon strain rather than Gtf2ird1 genotype. In addition,
specific analysis of genes previously identified as direct in vitro targets of GTF2IRD1 failed to show altered expression.
Conclusions/Significance: We have been unable to identify any in vivo neuronal targets of GTF2IRD1 through genome-wide
expression analysis, despite widespread and robust expression of this protein in the developing rodent brain.
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Introduction
Williams-Beuren Syndrome (WBS; OMIM 194050) is an
autosomal dominant microdeletion disorder, which occurs at a
frequency of about 1/7,500 live births, as a result of the deletion
of a 1.55 Mb region from chromosome 7q11.23 [1,2]. The
region is flanked by low copy repeats that, in rare instances, will
undergo unequal recombination during meiosis, resulting in
chromosomes with a deletion or duplication of the region [2].
The clinical symptoms of WBS are numerous, but commonly
include supravalvular aortic stenosis (SVAS), dysmorphic facial
features, hypersensitivity to sound, retarded growth, stellate
patterning of the iris, renal and dental abnormalities and
infantile hypercalcemia [2]. The complex phenotype also
includes behavioural and cognitive components. WBS is
characterized by mild to moderate intellectual disability with
relative strengths in verbal short-term memory and in language
and extreme weakness in visuospatial construction [3,4], as well
as anxiety, attention deficit hyperactivity disorder (ADHD) and
overfriendliness [5,6].
Of the more than 25 genes that are commonly deleted in WBS,
only one has been definitively linked to a phenotype. Hemizygosity
for, or point mutations in, the elastin gene (ELN) cause SVAS [7–
9]. Studies of individuals with atypical deletions in the WBS region
have implicated genes toward the telomeric end of the deletion
[10,11], and in particular the two transcription factor genes,
General Transcription factor 2 I (GTF2I) and GTF2I Repeat
Domain containing protein 1 (GTF2IRD1) [12–18] with the
majority of symptoms, including the cognitive and behavioural
phenotypes. We have previously generated Gtf2ird1
tm1Lro/tm1Lro
knockout mice (Gtf2ird1
2/2) that show low innate anxiety,
decreased aggression and increased social interaction [19], a
phenotype that shares similarities to the high sociability and
disinhibition seen in individuals with WBS [5]. Although no overt
differences in brain morphology were noted, adult mice had
selectively enhanced serotonin 1A receptor-mediated responses in
layer V pyramidal neurons of the pre-frontal cortex, suggesting
that brain function may be significantly impaired [20].
GTF2IRD1 is preferentially expressed in layer V of the adult
cortex [20,21] but shows a more widespread distribution and
higher expression during pre- and early post-natal brain
development. GTF2IRD1 is expressed throughout pre- and
post-implantation embryogenesis [22] [Allen Brain Atlas, http://
www.brain-map.org/] and analysis of mice expressing a LacZ
knock-in reporter showed expression throughout the midbrain and
hindbrain during the second half of gestation [23].
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transcription factor [24–26], few direct targets have been
identified, and to date these have not included plausible candidates
for the cognitive and behavioural phenotype seen in either
individuals with WBS, or Gtf2ird1
tm1Lro/tm1Lro mice. Using yeast-one
hybrids and/or in vitro expression analysis, GTF2IRD1 has been
implicated in the regulation of Tnni1, Hoxc8, Gsc, and Vegfr2
[24,25,27–29]. Genome-wide analysis in transformed mouse
embryonic fibroblast (MEF) lines identified 4,678 genes whose
expression was altered upon over-expression of GTF2IRD1
[30,31], although only a very small subset of these was validated
by quantitative PCR [31]. In addition, GTF2IRD1 has been
shown to bind to two distinct DNA consensus sequences,
GTCGAGATTAGBGA and CWGCCAYA, both of which are
found in the promoter regions of some of the proposed target
genes [26,32,33].
Given the presumptive role of GTF2IRD1 in the cognitive and
behavioural aspects of the WBS phenotype, the identification of
neural targets of this transcription factor would shed light on the
molecular pathways that are perturbed in WBS. Thus, we
undertook an in vivo screen to identify targets of GTF2IRD1 by
performing genome-wide microarray analyses of brain from
Gtf2ird1
2/2 mice at two different developmental time points. We
were not able to identify any genes whose expression was altered
by lack of GTF2IRD1, nor were we able to validate altered in vivo
alterations in expression of target genes previously identified
in vitro.
Results
Global expression analysis of Gtf2ird1
2/2 mouse brains
Microarray analysis of whole mouse brain was performed at two
different time points, embryonic day (E) 15.5 and post-natal day
(P) 0, to identify direct and indirect targets of GTF2IRD1 in an
unbiased manner. For P0 mice, cRNA was prepared from three
pools each of total RNA (nine mice per pool) extracted from
Gtf2ird1
2/2 and WT mice, and hybridized to the GeneChip
Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA).
Signals obtained were normalized using Robust Multiarray
Analysis (RMA) [34], and differences in gene expression were
detected using a second software program, Significance Analysis of
Microarrays (SAM) [35]. The data was submitted to the
ArrayExpress database under accession number E-MTAB-622.
Relatively few transcripts showed altered expression, and the
magnitudes of these changes were generally small (Table S1).
Using a false discovery rate (FDR) cut-off of 10%, eight genes were
identified as having changes in expression greater than 2-fold in
the Gtf2ird1
2/2 mice compared to WT littermates. An additional
79 genes had changes in expression between 1.2 and 2-fold.
For E15.5 mice, cRNA was prepared from total RNA extracted
from the heads of five Gtf2ird1
2/2 embryos and five WT
littermates, and hybridized to the Mouse WG-6 v2.0 Expression
BeadChip (Illumina, San Diego, CA). Differentially expressed
genes were detected using LIMMA [36], following normalization
of the log2 scale transformed data using the quantile normalization
method [37]. The data was submitted to the ArrayExpress
database under accession number E-MTAB-626.
Eighteen transcripts were found to have altered expression in
Gtf2ird1
2/2 mice, with an adjusted p-value of ,0.1 (Table S2).
Similar to the results from array analysis of P0 mouse brain, the
changes in expression detected in E15.5 embryos were generally
small with approximately half of the identified genes showing a
change of less than 2-fold.
Mospd3 and Auts2 were the only genes identified in both
microarray experiments, however, in P0 mouse brains Auts2 was
found to be increased by 1.3 fold, while in E15.5 embryos it was
found to be decreased by 1.5 fold.
Validation of microarray results
Quantitative reverse transcription PCR (qRT-PCR) was used to
validate alterations in gene expression detected in Gtf2ird1
2/2 mouse
brain using genome-wide microarray analysis. Where possible, qRT-
PCR primer pairs in which one of the primers overlapped with the
microarray probe sequence were used. The majority of expression
changes in protein coding genes could not be validated. Where gene
expression was found to be significantly different between genotypes,
the changes in expression were generally small, in concordance with
the microarray results (Figure 1A). Genes that showed the largest
changes in expression were Pex1, Stx3 and Mrpl16 with alterations of
3.57, 2.95, and 2.65 fold respectively, and AI506816 which was not
expressed at all in Gtf2ird1
2/2 mice.
qRT-PCR also failed to confirm altered expression of the
majority of genes found to be differentially expressed in the E15.5
embryos (Figure 1B). Significant differences in expression between
genotypes were only detected for seven genes, with the largest
changes in expression seen in Actl6b, Taf6 and Zfp68, with
alterations of 1.97, 1.63 and 1.39 respectively.
Altered expression detected in Gtf2ird1
2/2 mice was due
to a large genetic background effect
Many of the genes identified by microarray as being altered in
the P0 or E15.5 mice were located on distal chromosome 5, most
within 10 Mb of the Gtf2ird1 locus, and the genes with the largest
changes in expression in E15.5 embryos, Actl6b, Taf6, and Zfp68,
were all within 5 Mb of the Gtf2ird1 locus. The initial targeting of
Gtf2ird1 was performed in R1 embryonic stem (ES) cells (which are
derived from a 129X1/SvJ and 129S1 cross) and the mice were
backcrossed onto CD1 genetic background.
Analysis of strain-specific SNPs within the 39 UTR of Zfp68
revealed that Gtf2ird1
2/2 mice were homozygous for 12 of 13
129S1/SvImJ SNPs, while WT mice were only similar to the
129S1/SvImJ mice at 2 of 13 SNPs (Table 1). Although the
129S1/SvImJ mice are genetically very similar to the R1 line, they
are not identical, which is likely why one of the 129S1/SvImJ SNP
alleles was not present in the Gtf2ird1
2/2 mice. These results
indicate that a segment of chromosome 5 from the ES cell line
strain spanning Zfp68 and Gtf2ird1, and a minimum of 4.5 Mb,
had been retained in the Gtf2ird1
2/2 mice used for the E15.5
expression array.
qRT-PCR was then performed on whole brains from P0 mice
to determine if the expression differences detected between
Gtf2ird1
2/2 and WT mice were actually the result of strain
specific differences in expression between the CD1 and 129
genetic backgrounds. Expression of genes on chromosome 5 was
found to be the same in Gtf2ird1
2/2 mice as in WT 129S1/SvImJ
mice, and significantly different from that seen in CD1 WT mice
(Figure 2). Sequencing of the PCR amplicons was performed to
rule out differences in PCR efficiencies caused by strain specific
SNPs that might have existed within the primer binding
sequences. These results demonstrated that differences in expres-
sion detected in Gtf2ird1
2/2 mouse brain, relative to WT
littermates, were not dependent upon Gtf2ird1
2/2 genotype and
were not, therefore, the result of a lack of GTF2IRD1.
Expression of AI506816 and Pex1 had previously been validated
as significantly different between P0 Gtf2ird1
2/2 and WT CD1
mice, but upon qRT-PCR expression analysis to compare
background differences, no change in expression between
Genome-Wide Expression in Gtf2ird1 Knockout Mice
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2/2 and WT mice were identified. However, the altered
expression values in Gtf2ird1
2/2 mice from the original validation,
mirrored those seen in WT 129S1/SvImJ mice, suggesting that
although not located close to Gtf2ird1, the portion of chromosome
5 containing these adjacent genes was derived from the R1 ES cell
line in the mice used for the microarray experiment.
Differences in genetic background could not explain the
expression differences detected in Mrpl16 and Stx3 as they showed
significantly decreased expression in Gtf2ird1
2/2 mice relative to
both WT CD1 mice and WT 129S1/SvImJ mice (Figure 2).
siRNA knockdown of Gtf2ird1 in neuronal cell lines does
not affect expression of genes identified from microarray
analysis
To confirm whether expression differences detected for genes
on chromosome 5 were due to the presence of flanking DNA from
Table 1. A comparison of SNPs in the 39UTR Zfp68 in Gtf2ird1
2/2 mice and WT mice relative to 129S1/Sv1mJ mice.
SNP ID (dbSNP build 128) Map Position (NCBI Build 37) 129S1/SvImJ Allele Summary (all strains) Gtf2ird1
2/2 WT
rs38291282 Chr5: 139045176 T A/T T A
rs37309562 Chr5: 139045486 T C/T T C
rs36257731 Chr5: 139045921 G G/T G T
rs36653430 Chr5: 139045957 C C/T C T
rs36438231 Chr5: 139045989 G G/T G G
rs39288035 Chr5: 139046020 T G/T T G
rs39363663 Chr5: 139046416 C C/G C G
rs36967796 Chr5: 139046738 T C/T T T
rs36713208 Chr5: 139046762 G C/G C C
rs33378876 Chr5: 139047295 T C/T T C
rs33527435 Chr5: 139047340 A A/G A G
rs33143922 Chr5: 139047382 T A/T T T
rs29551605 Chr5: 139047411 A A/G A G
doi:10.1371/journal.pone.0023868.t001
Figure 1. qRT-PCR validation of expression changes identified by microarray. Expression values were normalized to the housekeeping
gene Sdha, and are depicted as a ratio of expression in Gtf2ird1
2/2 mice relative to WT littermates. * p,0.05, ** p,0.005 using Student’s t-test.
A. Expression in whole brain from P0 mice. RNA from 9 mice of the same genotype was pooled together to make cDNA (n=3 pools/genotype).
B. Expression in heads of E15.5 mouse embryos (n=5/genotype).
doi:10.1371/journal.pone.0023868.g001
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GTF2IRD1, siRNA knockdown of Gtf2ird1 was performed in two
neuroblastoma derived cell lines: Neuro2A and N1E-115. Eight
Gtf2ird1 siRNAs (Dharmacon, Lafayette, CO) were tested, and
those that resulted in the highest levels of knockdown were
combined into three different pools (A, B & C) to maximize the
level of knockdown. Each pool was then tested on both N2A and
N1E-115 cell lines in duplicate. Each of the three Gtf2ird1 siRNA
pools specifically knocked down Gtf2ird1 expression by ,60% in
Neuro2A cells and by ,80% in N1E-115 cells (Figure 3A).
Treatment with a non-targeting siRNA, or an siRNA targeting
Gapdh had no effect on the expression of Gtf2ird1. Gapdh siRNA
treated cells showed a specific 90% reduction in Gapdh expression
(data not shown).
Expression levels of 4 candidate genes identified in the
microarrays and verified using qRT-PCR were analyzed in
Gtf2ird1 siRNA treated cells. As there were no differences in the
effects between Gtf2ird1 pools A, B, and C, gene expression was
measured in cells treated with each pool (in duplicate) and the
expression values averaged together (n=6). No significant
differences in the expression of Actl6b, Taf6, Kin or Zfp68 could
be detected in Gtf2ird1 siRNA treated cells when compared with
either non-targeting siRNA treated cells or untreated cells
(Figure 3B). These results indicate that GTF2IRD1 does not play
a role in the transcriptional regulation of these genes in the cell
types examined, and that the expression differences detected by
microarray analysis were not the result of the disruption of
Gtf2ird1. Stx3 and Mrpl16 were not expressed in these cell lines and
the effect of Gtf2ird1 knockdown on their expression could not be
measured.
Stx3 and Mrpl16 show highly variable expression
When Stx3 and Mrpl16 expression was analyzed in P0 mice,
their expression in Gtf2ird1
2/2 and WT mice was highly variable.
These genes are located in a tail-to-tail orientation on mouse
chromosome 19, with only ,150 bp separating their 39 UTRs, an
orientation that is conserved in humans. To determine whether
Stx3 and/or Mrpl16 expression was dependent on Gtf2ird1
genotype or whether it was different in the initial Gtf2ird1
2/2
experimental group by chance, we examined expression in a larger
cohort of mice. Expression of both genes was measured in the
whole heads of five Gtf2ird1
2/2 and five WT E15.5 embryos.
Expression of each gene was measured using two different primer
sets: one pair that had been used previously and that amplified a
sequence from the 39 UTR, and one pair located further upstream
within an exon.
Expression of Stx3 and Mrpl16 exon sequences did not vary
greatly between mice regardless of genotype, however expression
of 39UTR sequences were variable and did not correlate with
genotype. Within each genotype, mice were detected that
displayed either high or low expression of both Mrpl16 and Stx3
(Figure 4A). Mice with low expression in the Mrpl16 39UTR also
had low expression in the Stx3 39 UTR and vice versa, likely due to
their overlapping tail-tail orientation.
Figure 2. qRT-PCR of candidate genes in P0 brain from mice of
different genetic backgrounds. Expression values are shown
relative to the housekeeping gene Sdha. (For presentation purposes,
some values were scaled as indicated). WT 129S1/SvImJ (n=7),
Gtf2ird1
2/2 (n=5), WT CD1 (n=6). * p,0.05, ** p,0.005 using
Student’s t-test.
doi:10.1371/journal.pone.0023868.g002
Figure 3. Knockdown of Gtf2ird1 in neuronal cell lines Neuro2A
and N1E-115. Expression values are shown relative to the house-
keeping gene Sdha. A. Three different pools of Gtf2ird1-siRNAs were
tested, each in two separate transfections. Expression of the
housekeeping gene Hmbs was not affected by siRNA treatment.
B. Expression of candidate genes in Gtf2ird1-siRNA treated neuronal
cell lines. Expression of genes transfected with each of the different
Gtf2ird1-siRNA pools were averaged together (n=6). No statistically
significant changes in expression were detected between Gtf2ird1-
siRNA treated cells and non-targeting siRNA treated or untreated cells
using Student’s t-test.
doi:10.1371/journal.pone.0023868.g003
Genome-Wide Expression in Gtf2ird1 Knockout Mice
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23868Expression of Stx3 was then examined in a second cohort to
determine if expression level was associated with Gtf2ird1
genotype. Expression was measured in whole brains from P0
(WT, n=15; Gtf2ird1
2/2, n=13) and adult (WT, n=12;
Gtf2ird1
2/2, n=12) mice. While the differences in expression
between WT and Gtf2ird1
2/2 P0 mice were marginally signifi-
cantly different (p=0.047), expression of Stx3 was still highly
variable in both genotypes (Figure 4A). Variability was also
detected in Stx3 expression in adult mice (Figure 4B), and the
differences in expression level between these genotypes were not
significant (p=0.899).
It is likely that the differences in both Stx3 and Mrpl16
expression that were detected represent natural expression
variation of these genes. As the expression differences were only
detected in the 39UTR and not in upstream coding sequences they
may be the result of alternative polyadenylation site selection and/
or splicing in the 39 UTR.
In vivo expression of GTF2IRD1 in vitro target genes was
not altered
Previous studies have used both a candidate gene approach and
unbiased global analyses to identify target genes of GTF2IRD1, in
vitro. We examined expression of some of these targets in vivo,i n
tissues from Gtf2ird1
2/2 mice using qRT-PCR. Expression of
bone morphogenetic protein receptor, type 1b (Bmpr1b) and
fibroblast growth factor 15 (Fgf15) were found to be highly
upregulated following Gtf2ird1 knockdown in C2C12 cells [33]. To
determine if GTR2IRD1 was involved in the regulation of Fgf15
and Bmpr1b in vivo, we measured expression of these genes in the
brains of Gtf2ird1
2/2 and WT mice, at P0, a developmental
timepoint when both genes were expressed. No genotype-specific
differences in gene expression were identified (Figure 5A),
suggesting that GTF2IRD1 does not play a role in the regulation
of Bmpr1b and Fgf15 in the newborn brain.
qRT-PCR was also used to look at the in vivo expression of
GTF2IRD1 candidate target genes identified in transformed
MEFs [30,31]. Primary MEFs were cultured from Gtf2ird1
2/2
(n=1), Gtf2ird1
+/2 (n=2) and WT (n=3) E15.5 littermate
embryos, and the expression levels of seven GTF2IRD1 in vitro
target genes were quantified (cyclin D3 (Ccnd3); cofilin 1 (Cfl1);
enhancer of zeste homolog 2 (Ezh2); fibrobalst growth factor 11
(Fgf11); enhancer of polycomb homolog 1 (Epc1); secreted
phosphoprotein 1 (Spp1 or Opn); transforming growth factor, beta
2( Tgfb2)). There were no significant differences in expression
between WT and heterozygous MEFs for any of the genes studied
(Figure 5B). MEFs were only cultured from one Gtf2ird1
2/2
embryo and so statistical analyses could not be completed,
however with the possible exception of Tgfb2, expression levels
in this embryo did not differ from WT or heterozygous littermates.
Based on these results, GTF2IRD1 is unlikely to regulate
expression of these genes in MEFs under the culture conditions
used. Expression of five target genes (LIM homeobox protein 1
(Lhx1); Cfl1; Fgf11; Opn; Tgfb2) was also determined in whole brain
from E18.5 and adult mice but no significant differences were
detected between genotypes for any of the genes (Figure 5C).
Discussion
There have been many studies showing that members of the
GTF2I gene family, including GTF2IRD1, are able to regulate
transcription by binding to specific DNA sequences. Thus, it was
surprising that we were unable to confirm any of the previously
identified GTF2IRD1 target genes in vivo, or identify any novel
targets in the brains of Gtf2ird1 knockout mice. Two different
microarray experiments looking at gene expression in the brains of
Gtf2ird1
2/2 and WT mice were unable to identify any genes that
were likely to be regulated by GTF2IRD1.
Comparison with other analyses of global gene
expression
The number of genes identified in each of our experiments, and
the magnitudes of the changes in expression were both smaller
than expected, given that more than 4600 genes with altered
expression were identified in MEFs that over-expressed
GTF2IRD1 [30,31]. This microarray experiment was performed
on transformed MEF cell lines which expressed Gtf2ird1 mRNA at
.7-fold above endogenous levels, and appeared to show even
higher levels of protein according to Western blot analysis [31].
Transformed MEFs likely have a very different expression profile
than the developing brain, since they are composed of a single cell
type and are undergoing rapid cell division. The different
endogenous global expression profiles, coupled with contrasting
levels of Gtf2ird1 expression (considerable over-expression in MEFs
vs. no expression in mice) may help explain why the results of our
global analysis of gene expression varied so greatly from that in
MEFs. In addition, only two biological replicates were used in the
analysis of MEFs, and .10-fold differences in expression were
reported between these replicates for some genes [31]. We used
three biological replicates of pooled samples in our first array
Figure 4. Expression of Stx3 and Mrpl16 show natural inter-
individual variation. Expression is shown relative to the housekeep-
ing gene Sdha. A. Expression in the heads of individual E15.5 mouse
embryos. Considerable variation in expression within the 39 UTR can be
seen for both genes within each genotype group. Each bar on the
graph represents the expression level of an individual mouse, and the
same 10 mice are shown in the same order for each primer pair.
B. Expression of Stx3 in P0 and adult brain from Gtf2ird1
2/2 mice and
control littermates. Each dot represents the expression of Stx3 in an
individual mouse, and horizontal bars represent the mean expression
level for the group.
doi:10.1371/journal.pone.0023868.g004
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array experiment, to account for inter-animal differences.
A second global analysis of gene expression in vivo has been
reported recently [38]. This analysis was performed on a different
Gtf2ird1 knockout mouse model, Gtf2ird1
Gt(XE465)Byg/Gt(XE465)Byg
(Gtf2ird1
Gt/Gt), generated from a gene trap ES cell line. This study
found 536 genes with altered expression in E9.5 Gtf2ird1
Gt/Gt
embryos, however there are several caveats to the interpretation of
these data. Firstly, Gtf2ird1
Gt/Gt embryos die between E8.5 and
E12.5, with most showing signs of being actively resorbed by E9.5
[38]. Thus, it is likely that much of the altered gene expression
may have been due to processes involved in embryonic death and
resorption. Secondly, the Gtf2ird1
Gt/Gt mouse has a far more severe
phenotype than the other four published Gtf2ird1 mouse models
[19,23,39,40]. In all these other models, homozygous mice are
healthy and fertile, with milder phenotypes such as behavioural
and cognitive deficits or craniofacial abnormalities. As discussed
previously [40,41], the embryonic lethality observed in the
Gtf2ird1
Gt/Gt mice likely stems from the use of a gene trap ES
cell line with an insertion into intron 22 of Gtf2ird1. The resulting
transcript would lead to translation of a fusion protein encom-
passing most of GTF2IRD1, which may still interact with its usual
protein partners but be incapable of carrying out its normal
function. If indeed the case, the downstream effects on global gene
expression would be likely to include effects on genes that are not
normally either direct or indirect GTF2IRD1 targets.
Strain-dependent differences in gene expression
predominate in array analysis of Gtf2ird1
2/2 mice
A number of the genes we identified as having decreased
expression in brains using microarray analysis were good
candidate genes for the behavioural phenotype seen in
Gtf2ird1
2/2 mice. ACTL6B is a member of a post-mitotic
neuron-specific chromatin remodelling complex, and is known to
be involved in dentritic growth and development [42]. STX3 is
known to be involved in neuronal growth [43] and synapse
function [44]. However, while expression of these genes was
verified by qRT-PCR, the expression differences are unlikely to be
linked to the disruption of GTF2IRD1.
In the case of Actl6b, we believe that its altered expression is
related to strain background, rather than to Gtf2ird1 genotype. All
genes identified through microarray analysis of E15.5 embryos,
and many identified through microarray analysis of P0 mice, were
located on the distal portion of chromosome 5, most within 10 Mb
of the Gtf2ird1 locus at 135 Mb. This clustering of candidate
target genes around Gtf2ird1 could have resulted from a disruption
of transcriptional regulation due to the targeting itself, perhaps due
to the presence of the neomycin cassette used for ES cell selection,
however genes immediately adjacent to Gtf2ird1 showed un-
changed expression [19], suggesting that the targeting itself had
minimal effect. Our mice were generated from the R1 ES cell line
[129X1/SvJ-129S1 hybrid] and backcrossed onto CD1. By
selecting for the targeted Gtf2ird1 allele, we were also selecting
for mice where the surrounding region of chromosome 5
originated in the ES cell line.
The phenomenon of retained ES cell-derived DNA flanking a
targeted locus confounding the results of microarray experiment is
a recognized problem [45–47]. Many polymorphisms exist which
result in altered levels of gene expression between different mouse
strains [48], thus, a mouse with a targeted allele may express the
genes surrounding the targeted locus at different levels than the
WT mouse to which it is being compared, even if littermates are
used. This flanking gene effect has been shown to persist after 11
generations of back crossing and extend up to 40 MB from the
targeted locus [47].
To further confirm that in vivo differences in gene expression
were unrelated to Gtf2ird1 genotype, we used siRNA to knockdown
Gtf2ird1 expression in vitro in two neuronal cell lines. This allowed
the expression of candidate genes to be studied in the absence of
physical disruption of chromosome 5. Even with Gtf2ird1
knockdown at 80%, we were unable to validate any of the genes
identified in the microarray experiments. Since we were able to
detect differences in candidate gene expression even in Gtf2ird1
+/2
mice (data not shown), we would have expected to see a significant
change in expression in the siRNA treated cells, were the
candidate genes being either directly or indirectly regulated by
GTF2IRD1.
Why in vivo differences in global gene expression were
not found in Gtf2ird1
2/2 mice
Given the large number of potential GTF2IRD1 targets
previously identified in vitro, and the widespread expression of
Figure 5. qRT-PCR of previously identified in vitro targets of GTF2IRD1. Expression values were normalized to the housekeeping gene Sdha,
and are depicted as a ratio of expression in Gtf2ird1
2/2 or Gtf2ird1
+/2 mice relative to WT. No statistically significant differences in expression were
detected between genotypes using Student’s t-test. A. Expression of Bmpr1b and Fgf15 in whole brain of P0 mice (n=3/genotype). B. Expression of
previously identified in vitro targets of GTF2IRD1 in primary MEFs. MEFs were cultured from WT (n=3), Gtf2ird1
+/2 (n=2), and Gtf2ird1
2/2 (n=1)
E15.5 mouse embryos. Hmbs is a housekeeping gene and was used as a control. C. Expression of previously identified in vitro targets of GTF2IRD1 in
whole brains. E18.5 (n=3/genotype), adult (WT, n=3; Gtf2ird1
2/2, n=2) mice. Hprt is a housekeeping gene and was used as a control.
doi:10.1371/journal.pone.0023868.g005
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not identify any bone fide changes in gene expression using
microarray analysis of both newborn and mid-gestation knockout
mice.
There are a number of possible explanations as to why no in vivo
targets of GTF2IRD1 were identified. It may be that GTF2IRD1
does not regulate gene expression at the time points examined,
although this is unlikely given its expression pattern. Regulation of
target genes may only occur in very specific cell populations in the
brain, and by examining whole brain, any effect was diluted out,
but again, the widespread distribution of GTF2IRD1 in brain
suggests otherwise.
Another possibility is that the absence of GTF2IRD1 does affect
gene expression in Gtf2ird1
2/2 mice, but that the changes in
expression are small, and so fall below the threshold of detection.
This was the case when gene expression was analyzed by
microarray in mice deficient for the general transcriptional
repressor, methyl CpG binding protein 2 (Mecp2) [49]. Microarray
analysis performed on brain from Mecp2
2/2 mice at multiple time
points did not detect any significant changes in gene expression.
However, mutant mice could be differentiated from WT
littermates by looking at very subtle changes in gene expression
that occurred in a number of genes in parallel. It is possible that
deficiency of GTF2IRD1 also only causes subtle changes in gene
expression, which are sufficient to cause the behavioural
phenotype seen in Gtf2ird1
2/2 mice but hard to detect using
microarray.
An alternate theory to explain the lack of in vivo transcriptional
targets for GTF2IRD1 is that the main function of this protein is
not transcriptional activation or repression. GTF2IRD1 may not
regulate gene expression in vivo, but instead may be involved in
protein-protein interactions in the absence of biologically relevant
DNA binding. A cytoplasmic role for GTF2I has been
demonstrated. GTF2I belongs to the same protein family as
GTF2IRD1 and can negatively regulate agonist-induced calcium
entry into cells by indirectly inhibiting the localization of subunits
of the transient receptor potential cation channel, TRPC3, to the
plasma membrane [50]. Proper regulation of intercellular calcium
levels via TRPC channels is essential for many neuronal functions
including axon guidance [51] and membrane depolarization [52],
and disruption of another member, TRPC5, reduces innate fear
[53]. It is possible that GTF2IRD1 may also play a cytoplasmic
role in developing brain, or other tissues. Reports of the
localization of GTF2IRD1 within the cell are conflicting, in part
due to the lack of a specific antibody, necessitating the over-
expression of tagged protein [29,54,55], so it may yet be shown to
have a role outside the nucleus.
Why GTF2IRD1 gene targets identified in vitro were not
validated in vivo
Having failed to identify any genotype-dependent changes in
gene expression using an unbiased genome-wide approach, we
investigated direct targets of GTF2IRD1 previously identified in
vitro, in our mouse model. Of the ten genes that we analyzed, none
showed altered expression in either developing or adult brain, or
in MEFs. Expression of Bmpr1b and Fgf15 had been shown to
increase by 600- and 6900-fold, respectively, in a Gtf2ird1-siRNA
treated C2C12 myoblast cell line, and GTF2IRD1 was shown to
bind to the Ffg15 promoter using chromatin immunoprecipitation
(ChIP) [33]. The absence of any detectable effect on the expression
of either of these genes in mice that lack GTF2IRD1 suggests that
if GTF2IRD1 does play a role in the regulation of these genes, it
may be dependent upon co-factors that are expressed in C2C12
cells but not in brain.
We also investigated in vivo expression of eight other target genes
previously identified in vitro, but did not find any altered expression
in either primary MEFs or brain tissue from Gtf2ird1
+/2 or
Gtf2ird1
2/2 mice. These genes had been identified through
GTF2IRD1 over-expression studies in MEFs [31], GTF2IRD1
had been shown to bind to the promoter regions of six of them
using ChIP, and each of them demonstrated at least a two-fold
decrease in expression with double knockdown of Gtf2ird1 and
Gtf2i using siRNA (with the exception of Fgf11 which showed 1.3-
fold up-regulation) [30].
It is possible that binding of GTF2IRD1 to the promoters of
these genes, and subsequent regulation of gene expression is
dependent upon co-factors which are not found in the brain, or
that GTF2IRD1 regulates their transcription in a specific type or
subpopulation of cells. However, recently, it has been shown that
GTF2IRD1 may need at least two, closely adjoining, consensus
binding sequences to be present within a gene promoter in order
to facilitate robust protein binding in vivo [40]. This finding
contradicts the in vitro evidence for GTF2IRD1 binding to the
promoter of genes such as Tnni1 [56,57], Hoxc8 [27] and Gsc [28],
as well as the genes tested in this study, since they all contain a
single GTF2IRD1 binding consensus sequence.
Summary
In conclusion, this study failed to identify new in vivo targets or to
validate previously identified in vitro targets of GTF2IRD1 in mice
with homozygous disruption of this gene. The biological
mechanism by which loss or reduction of GTF2IRD1 leads to
the behavioural phenotype in mice or in people with WBS,
therefore remains unknown. The robust phenotype seen even in
mice missing a single copy of Gtf2ird1 [19] suggests that this
protein does play an important role in proper brain development
and/or function but additional experiments will be needed to shed
light on the precise role of GTF2IRD1. These could include the
identification of interacting proteins in the tissues and time-points
of particular relevance as well as the isolation of specific cell
populations that express GTF2IRD1.
Materials and Methods
Isolation of tissues and RNA
All procedures were approved by the University of Toronto
Animal Care Committee and carried out in compliance with the
Canadian Council on Animal Care guidelines (U of T Protocol #
20008762). Animals were housed with access to food and water ad
libitum and were on a 12 hour light/dark cycle throughout the
experiments. Gtf2ird1
tm1Lro/tm1Lro mice (Gtf2ird1
2/2) were generated
as described previously [19]. Mice were maintained on a CD1
background and had reached the 4th generation of backcrossing at
the time of these experiments. For all experiments using embryos,
Gtf2ird1
2/2 mice and WT littermates were generated through the
intercrossing of Gtf2ird1
+/2 mice. Male and female mice were
housed together overnight, and the female was checked for a
vaginal plug in the morning. 12:00 pm on the day the plug was
found was considered to be E0.5. Data were pooled across all male
and female pups within genotype groups.
P0 mice were sacrificed by decapitation, and adult mice by
cervical dislocation. Whole brain was removed and immediately
flash frozen in liquid nitrogen and tail tissue collected for DNA
extraction and genotyping. For embryonic dissections, the mother
was sacrificed using cervical dislocation, the uterus removed,
embryos immediately dissected from the yolk-sacs, the heads
removed and flash frozen in liquid nitrogen. Tissues were
homogenized in TriReagent (Sigma-Aldrich Canada, Oakville,
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the manufacturers protocol. Total RNA used for microarray
analysis was cleaned up using the RNeasy kit (Qiagen,
Mississauga, ON).
Microarray analysis using the Affymetrix mouse 430 2.0
gene chip
RNA from individual P0 mouse brains were pooled together in
equal concentrations. Three pools containing RNA from nine WT
mice were created, along with three pools containing RNA from
nine Gtf2ird1
2/2 mice. Microarray analysis was performed by The
Centre for Applied Genomics (TCAG) at the Hospital for Sick
Children (Toronto, ON) using the GeneChip Mouse Genome 430
2.0 Array (Affymetrix)(which contains probes for over 39,000
transcripts) following the manufacturer’s protocol. The signals
from the gene chips were normalized using Robust Multiarray
Analysis (RMA) [34]. Differences in gene expression were detected
using a second software program, Significance Analysis of
Microarrays (SAM) [35], which uses q values as a measure of
the false discovery rate.
Microarray analysis using the Illumina mouseWG-6 v2.0
BeadChip
RNA from five Gtf2ird1
2/2 mice and five WT littermates were
used for microarray analysis. Microarray analysis was performed
by TCAG at the Hospital for Sick Children (Toronto, ON) using
the Illumina Mouse WG-6 v2.0 Expression BeadChip (which
contains probes for over 45,200 transcripts) following the
manufacturer’s protocol. Analysis of microarray data was
performed by the Statistical Analysis Core Facility at TCAG.
The data pre-processing included three steps: background
correction was performed in the Beadstudio program (Illumina),
the data was then transferred to log2 scale and quantile
normalization was performed [37]. Differentially expressed genes
were identified using LIMMA (linear models for microarray data)
[36]. All data is MIAME compliant and that the raw data has been
deposited in the ArrayExpress database under the accession
numbers E-MTAB-622 and E-MTAB-626.
Expression analysis using quantitative real-time PCR
Following extraction, total RNA samples were treated with
DNase (Turbo DNA free, Applied Biosystems/Ambion, Austin,
TX) and 5 ug of RNA converted to cDNA using the Superscript II
First-Strand Synthesis System (Invitrogen Canada, Burlington,
ON) and random hexamer primers. cDNA samples were diluted
1/100 with sterile water and subjected to real-time PCR analysis
using the Power SYBR Green PCR Master mix (Applied
Biosystems, Foster City, CA) and the ABI Prism 7900HT
sequence detection system (Applied Biosystems) as previously
described [19]. Primers used for expression analysis are listed in
Table S3. Samples were run in triplicate, and each experiment was
repeated at least twice with consistent results. Absolute quantifi-
cation analysis was used; each plate included a no template
control, serially diluted concentrations of control genomic DNA
(range 0.63–10 ng/well) to generate a standard curve for
transcript quantification and a no reverse transcriptase control to
ensure the cDNA was free of genomic contamination. All test
genes were normalized to the housekeeping gene succinate
dehydrogenase (Sdha). Normalized values for each gene were then
averaged for each genotype group. Comparative expression ratios
(%) were calculated by dividing the averaged normalized values for
each of the test genes in the Gtf2ird12/2 group by the
normalized test gene values for the WT group.
siRNA knockdown of Gtf2ird1 in neuronal cell lines
siRNA knockdown of Gtf2ird1 was performed in two different
neuroblastoma derived cell lines: Neuro2A (N2A; ATCC #CCL-
131) and N1E-115 (ATCC # CRL-2263). Cell lines were
maintained in D-MEM (Sigma-Aldrich) with 10% fetal bovine
serum (FBS) (Invitrogen) and 16 penicillin-streptomycin (Sigma-
Aldrich). For siRNA transfection, cells were cultured in D-MEM
+10% FBS without antibiotics. Cells were maintained at 37u C
with 5% C02.
siRNAs targeting Gtf2ird1 (Table S4), Gapdh (ON-TARGETplus
GAPD Control Pool (Mouse)) and a non-targeting control (ON-
TARGET plus Non-targeting siRNA #1) were obtained from
Dharmacon. Transfections of siRNA into N2A and N1E-115 cells
were conducted using Lipofectamine 2000 (Invitrogen) following
the manufacturer’s protocol. Briefly, cells were transfected in 6-
well plates at 50–60% confluency. Lipofectamine 2000 was diluted
1/50 in Opti-MEM Reduced Serum Medium (Invitrogen), and
siRNAs were diluted similarly to a final concentration of 100 nM.
Cells were harvested at 24 hrs following transfection and total
RNA was extracted.
Preparation and culture of mouse embryonic fibroblasts
(MEFs)
Embryos were harvested from the pregnant mother at E15.5
and yolk-sacs collected for genotyping. The embryos were
dissected from the uterus into sterile PBS, the head, limbs and
internal organs were removed from the embryos, and the carcasses
washed three times with sterile Dulbecco’s Modified Eagles
Medium (D-MEM) (Sigma-Aldrich). Embryos were then minced
into small pieces, trypsinized, washed and plated in D-MEM
+10% FBS and 16penicillin-streptomycin (Sigma-Aldrich). Cells
were cultured at 37u C with 5% C02 and passaged at least twice
before use to ensure a homogenous population.
Supporting Information
Table S1 Genes found to have altered expression in the brains of
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Table S2 Genes found to have altered expression in the brains of
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